Connecticut saw a drop in Respiratory Syncytial Virus, or RSV, cases during the 2025 season, according to statistics by the state Department of Public Health (DPH). RSV season ...

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations ...

and respiratory syncytial virus (RSV) season. The committee will vote on flu and RSV, the docket says, but so far it does not mention COVID-19 votes. In addition, RSV votes from the committee's April ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Early evidence shows that nirsevimab substantially reduced emergency bronchiolitis cases and hospital admissions in infants ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...